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Summary The immunotoxin BU12-SAPORIN was constructed by covalently coupling the single-chain
ribosome-inactivating protein saporin to the anti-CD19 monoclonal antibody BU12 via a disulphide linker
using the heterobifunctional reagent SPDP. The immunoreactivity and specificity of BU12-SAPORIN was
identical to that of unmodified native BU12 antibody. BU12-SAPORIN was selectively cytotoxic in vitro in a
dose-dependent manner for the CD19+ human common acute lymphoblastic leukaemia (cALL) cell line
NALM-6 but exhibited no toxicity for the CD19- T-cell acute lymphoblastic leukaemia (T-ALL) cell line
HSB-2. The survival of severe combined immunodeficient (SCID) mice with disseminated NALM-6 leukaemia
was significantly prolonged compared with sham-treated control animals by a course of therapy with
BU12-SAPORIN but not with the irrelevant anti-CD7 immunotoxin HB2-SAPORIN. BU12-SAPORIN had
no therapeutic effect in SCID mice with disseminated CD19- HSB-2 leukaemia. These preclinical studies have
clearly demonstrated the selective cytotoxicity of BU12-SAPORIN for CD19+ target cells both in vitro and in
vivo. This, taken together with the lack of expression of the CD19 molecule by any normal life-sustaining
tissue and its ubiquitous and homogeneous expression by the majority of cALL and B-NHL cells, provides the
rationale for undertaking a phase I trial of systemic therapy with BU12-SAPORIN.
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Various phase I/II clinical trials of systemic immunotoxin
therapy for a variety of haematological malignancies have
been completed or are currently in progress (Vitetta et al.,
1993). Two main target molecules, CD19 and CD22, have so
far been exploited clinically for toxin delivery to malignant B
cells. CD22 has proven an excellent target molecule in terms
of the potency of immunotoxins made with antibodies recog-
nising this B-cell structure (Shen et al., 1988). However,
expression of CD22 is quite heterogenous within B-cell
tumours, often with only a,small percentage of tumour cells
expressing this molecule. This obviously limits the value of
CD22 as target molecule in the context of immunotoxin-
based therapies in which delivery of toxin to all individual
tumour cells is required to ensure total ablation of the neo-
plastic clone.
CD19 on the other hand is a pan B-cell cell-surface diff-
erentiation structure that appears early in ontogeny and is
expressed by the majority of pre-B and B-cell tumours with
the exception of myeloma (Ling et al., 1987). Moreover, in
general CD19 is homogeneously expressed by the vast
majority of cells within a given B-cell tumour which includes
B-cell non-Hodgkin's lymphoma and pre-B-cell acute lym-
phoblastic leukaemia (Schuurman et al., 1987). These charac-
teristics make CD19 an ideal target molecule for toxin
delivery to malignant B cells. However, immunotoxins con-
structed with anti-CD19 antibodies are generally less potent
than those constructed with anti-CD22 antibodies (Ghetie et
al., 1988).
Three anti-CD19 immunotoxins have been reported in
clinical use. B4-bR comprises the anti-CD19 antibody B4
coupled via a disulphide linker to blocked ricin (intact ricin
in which the two galactose-binding domains of the B-chain
have been chemically blocked) ha been investigated in two
separate phase I trials in patientA with advanced B-cell
tumours (Grossbard et al., 1992, 1993b) and more recently in
a phase I study in patients in complete remission with B-cell
lymphoma following autologous bone marrow transplanta-
tion (Grossbard et al., 1993a). HD37-dgR is an immunotoxin
comprised of deglycosylated ricin A chain coupled via a
hindered disulphide linker to the anti-CDl9 antibody HD37
and has also been used in a phase I clinical study (Conry et
al., 1994). B43-PAP uses the single-chain ribosome-inact-
ivating protein, pokeweed antiviral protein (PAP) coupled via
a non-hindered disulphide bond to the B43 antibody. In
formal phase I clinical trials, all three of these reagents have
shown anti-tumour activity in a variable proportion of
therapy-resistant patients, most notably B43-PAP in an
ongoing phase I study has induced four complete responses
in patients with multiply relapsed common acute lymphoblas-
tic leukaemia (cALL). Saporin has never been targeted
against CD19 in clinical trials in man though it has been
used in immunotoxin form in four patients with Hodgkin's
lymphoma using the anti-CD30 antibody Ber-H2 (Falini et
al., 1992), and major transient responses were observed.
We report here preclinical investigations with a new anti-
CD19 immunotoxin BU12-SAPORIN which uses the single-
chain ribosome-inactivating protein saporin coupled via a
non-hindered disulphide bond to BU-12 antibody. BU12-
SAPORIN is clearly demonstrated to be highly selective at
delivering saporin only to CD19+ B-cell lines in vitro and to
be therapeutically effective in vivo in a SCID mouse model of
human CD19+ pre-B-cell acute lymphoblastic leukaemia.
These preclinical studies provide the rationale for taking
BU12-SAPORIN into a phase I clinical trial in patients with
advanced therapy refractory B-cell tumours.
Materials and methods
SCID mice
Pathogen free BALB/c.C57BL/KaIgh-l/ICR scid/scid (SCID)
mice of both sexes 6-10 weeks of age were produced from
our own breeding colony and used in all the experimental
work described here. The breeding colony is maintained
under sterile conditions inside a laminar flow isolator and
animals are housed on sterile bedding and provided with
sterile water and food ad libitum. Animals for experimental
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use were transferred out from the isolator to autoclaved filter
top microisolator cages and housed on sterile bedding as five
single-sex animals per cage. These animals were also provided
with sterile water and food ad libitum and all manipulations
with these animals were carried out in a laminar flow hood
by personnel using aseptic techniques.
NALM-6 and HSB-2 human leukaemia cell lines
The CD19+ CD7- Pre-B leukaemia cell line NALM-6 was
originally established from the peripheral blood of a 19-year-
old male with non-T non-B acute lymphoblastic leukaemia
(Hurwitz et al., 1979). The CD7+ CD19- human cell line
HSB-2 was originally established from peripheral blood
leukaemic blasts from a 4-year-old paediatric patient with
terminal T-cell acute lymphoblastic leukaemia (Adams et al.,
1970). Both NALM-6 and HSB-2 cells were maintained in
the logarithmic phase of growth in culture flasks containing
antibiotic-free RPMI medium (Integra Biosciences, Northum-
bria, UK) containing 10% fetal calf serum and supplements
of 2 mM sodium pyruvate and 2 mM glutamine (referred to
hereafter as RIO medium) at 37°C under a humidified atmo-
sphere of 5% carbon dioxide.
Saporin production
Seeds of the soapwort plant, Saponaria officinalis, were
kindly supplied by Chiltern Seeds, Ulverston, Cumbria, UK.
Saporin was extracted from seeds by the method of Stirpe et
al. (1983) and purified to homogeneity by a combination of
cation exchange chromatography on carboxymethyl-Seph-
arose and gel filtration on Sephacryl-S200HR. The final
product gave a single band of 29 500 daltons on SDS-PAGE
and was immunoreactive on ELISA with both polyclonal and
monoclonal anti-saporin antisera.
BU-12 antibody production
The anti-CD19 antibody-producing hybridoma clone BU-12
was produced by the immunisation of two BALB/c mice with
the Burkitt's lymphoma cell line EB4. Immune spleen cells
from these animals were fused according to a modified
method of Kohler and Milstein (1975) with the mouse X63
AG8 653 plasmacytoma cell line and resulting hybridomas
selected in HAT medium. Screening of hybridoma culture
supernatants on a range of T-, B-, myeloid and erythroid cell
lines and on sections of normal human tonsil led to the
selection of the pan-B-cell-reactive BU-12 hybridoma clone.
The BU-12 antibody is of the IgG, subclass and was
clustered and designated as an anti-CD19 antibody at the
Third Leucocyte Typing Conference (B-cell section antibody
no. 025) held in Oxford, UK in 1986 (Ling et al., 1987).
Bulk BU-12 antibody was manufactured by inoculating
5 x 108 BU-12 cells into an Endotronics Accusyst R hollow-
fibre bioreactor (Endotronics, Minneapolis, MI, USA) acc-
ording to the manufacturer's instructions with some minor
modifications. Harvested antibody-containing culture super-
natants were concentrated on a Sartorius cross-flow filtration
apparatus (Sartorius, Epsom, UK) equipped with a 30000
MW cut-off sanitisable cellulose acetate membrane. BU-12
antibody was purified to homogeneity from culture super-
natants by a combination of ammonium sulphate precipita-
tion, anion exchange chromatography on DEAE-Sepharose
(Sigma, Poole, UK) and Sephacryl-S200HR (Sigma) gel
filtration. Purified antibody gave a single band of 160000
daltons on SDS-PAGE under non-reducing conditions and
retained full immunoreactivity as demonstrated by flow
cytometry.
BU-12 SAPORIN immunotoxin construction
BU-12 SAPORIN immunotoxin was constructed by con-
jugating the BU-12 antibody to saporin with the hetero-
bifunctional cross linking reagent N-succinimidyl 3-(2-
pyridyldithio) propionate (SPDP) as described by Thorpe et
al. (1985). BU12-SAPORIN prepared in this way contained a
non-hindered disulphide bond between antibody and saporin.
Free antibody was removed from the immunoconjugates by
carboxymethyl-Sepharose (Sigma) cation exchange chroma-
tography as described previously (Lambert et al., 1985).
Purified BU12-SAPORIN was dialysed into phosphate-
buffered saline (PBS) pH 7.2, sterilised by passage through a
0.2 ltm filter and stored deep frozen in aliquots at - 80°C.
HB2-Sap immunotoxin
The preparation, characteristics and performance of the anti-
CD7 immunotoxin HB2-Sap have been described in detail by
us previously (Flavell et al., 1994; Morland et al., 1994).
Sodium dodecyl sulphate polyacrylamide gel electophoresis
(SDS-PAGE) analysis
SDS-PAGE analysis according to the method of Laemmli
(1970) was used to confirm purity of antibody, saporin and
immunotoxins. Five per cent non-reducing SDS-PAGE gels
with 3% stacking gels were routinely used for separations.
Aliquots of 20 lg of each immunotoxin, HB2 antibody or
saporin were added to individual wells following boiling in
non-reducing sample buffer. Following electrophoresis gels
were stained with Coomassie blue.
Flow cytometry
The binding of BU12-SAPORIN to NALM-6 or HSB-2 cells
was confirmed and compared with that obtained for the
native BU12 antibody by flow cytometry. One million
NALM-6 or HSB-2 cells were incubated with concentrations
of BU12-SAPORIN or native BU12 antibody diluted in PBS
pH 7.2 (range OAMl-l0 gml-') for 30min at 4°C in the
presence of 0.1% sodium azide. Negative control cells were
incubated in PBS only. For staining samples of fresh cALL
cells BU-12 antibody was conjugated directly to fluoroescein
isothiocyanate (FITC) and binding measured directly by flow
cytometry. For unconjugated BU-12 antibody, following
staining, cells were washed twice in cold PBS containing
0.1% sodium azide and the cell pellets incubated for a fur-
ther 30 min in 100,ul of FITC-labelled Fab2 rabbit anti-
mouse immunoglobulins (Sigma) diluted 1:20 in PBS. Cells
were washed twice in PBS, resuspended in cold PBS and
surface fluorescence analysed on a Becton Dickinson FACS-
can equipped with analytical software.
Immunocytochemistry
Fresh normal human tissues (listed in Table I) were snap
frozen in liquid nitrogen and 5 ILM thin sections cut. Sections
were fixed in the dry acetone and stained with BU-12
antibody. Bound BU-12 was detected using a standard strep-
tavidin immunoperoxidase system with diaminoazobenzidine
as chromogen.
Direct antibody rosette assay
The direct antibody rosette test (Ling and Richardson, 1981)
was used to determine CDl9 expression (detected by BU-12
antibody) in a wide variety of fresh B-cell non-Hodgkin's
lymphomas.
Protein synthesis inhibition assay
The ability of individual immunotoxins to inhibit protein
synthesis in target cell lines was evaluated using a [3H]leucine
uptake assay described by us previously (Flavell et al., 1991).
Briefly, triplicate cultures of 1 x 105 Target NALM-6 or
HSB-2 cells were exposed to individual concentrations of
BU-12 SAPORIN or HB2-Sap immunotoxin (range 0.0001-
l10Lgml'1), saporin (range 0.Ql-20ligmlh') or BU-12
antibody (range 0.01-10fLgml-') in RIO medium. Control
1
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TableI Immunoreactivity ofBU12 MAband BU12-SapITonarangeofnormalhuman
tissues
Tissue
Immunoreactivity
BU12 MAb BU12-Sap IT
Adrenal
Bladder (including ureters)
Brain
Cartilage
Endothelium
Heart
Kidney
Large intestine
Liver
Lung
Lymph node
Pancreas
Peripheral nerve
Pituitary
Skin
Small intestine
Spinal cord
Spleen
Stomach
Testis
Thymus
Tonsil
Trachea
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Positive B-cell follicles
Negative
Negative
Negative
Negative
Negative
Negative
Positive B-cell follicles
Negative
Negative
Negative
Positive B-cell follicles
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Positive B-cell follicles
Negative
Negative
Negative
Negative
Negative
Negative
Positive B-cell follicles
Negative
Negative
Negative
Positive B-cell follicles
Negative
cultures were incubated in RIO medium only. Cultures were
incubated at 37°C for 48 h in a humidified atmosphere of 5%
carbon dioxide/95% air. After this period of time 1 pCi of
[3H]leucine was added to each culture and incubated for a
further 14-16 h. Cells were harvested onto glass fibre discs
using a Skatron Combi cell harvester (Skatron, Lier, Nor-
way) and individual discs counted for radioactivity on a
Packard 1600TR scintillation analyser (Canberra Packard,
Pangbourne, UK). Results were expressed as a percentage of
control values. The ICm value was calculated as the concen-
tration of immunotoxin which inhibited protein synthesis in
target cells by 50% relative to controls.
Establishment ofNALM-6 or HSB-2 leukaemia in SCID mice
NALM-6 or HSB-2 human leukaemia cells were injected
intravenously into SCID mice in a 2001l volume of RIO
medium.
Therapy ofleukaemia-bearing SCID mice with immunotoxins
Groups of ten (five male and five female) SCID mice, 6-10
weeks of age received 2 x 106 NALM-6 or HSB-2 cells in-
travenously. Seven days after injection oftumour cells appro-
priate groups received 3 x 10jg doses of BU12-SAPORIN,
HB2-Sap, BU-12 antibody + saporin (8jg +2 fig) or sham
therapy with PBS, each injection being given intravenously
on alternate days (i.e. 7, 9 and 11 days after injection of
tumour cells). Each injection was given in 200 il of PBS as
solvent. Animals were observed on a daily basis and those
showing signs of hind leg paralysis (SCID-NALM-6 animals
only) or which became moribund were painlessly killed and
subjected to post-mortem examination. All major organs
were removed for histopathological examination to confirm
the presence of disease.
Results
SDS-PAGE analysis ofBU12, saporin and BU12-SAPORIN
Results of SDS-PAGE analysis of BU12-SAPORIN imm-
unotoxin under non-reducing conditions are shown in Figure
1. Two bands of 190 and 220 kDa were detected correspon-
ding to species of immunotoxin comprising one antibody
molecule coupled to one or two saporin molecules respec-
Figure 1 SDS-PAGE analysis on a non-reducing 5% separating
gel of BUl2-SAPORIN (lane 1), BUl2 antibody (lane 2) and
saporin (lane 3). Molecular weights shown are in kDa.
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tively (lane 1). The relative proportions of the 190 and
220 kDa immunotoxin species was approximately 3:1. Less
than 1% free BU12 antibody or saporin was detectable in the
BU12-SAPORIN. BU12 antibody (lane 2) gave a single band
of 160 kDa and saporin (lane 3) a single band of 29.5 kDa.
Binding characteristics ofBU12 and BU12-SAPORIN to
NALM-6 and HSB-2 cells.
Results of flow cytometric analysis of BU12 antibody and
BU12-SAPORIN IT binding to NALM-6 cells are shown in
Figure 2. BU12 and BU12-SAPORIN stained NALM-6 cells
with equal intensity when used at a saturating concentration
of 10 fig ml- ' or a subsaturating concentration of 1 fig ml- .
BU12 or BU12-SAPORIN immunotoxin did not stain the
CDl9- cell line HSB-2 (data not shown).
Normal tissue staining with BUI2 and BU12-SAPORIN
The staining characteristics of BU12 antibody and BU12-
SAPORIN immunotoxin were studied on a wide variety of
normal human tissues and the results are listed in Table I.
Both performed identically and stained only B lymphocytes
within the B-cell compartments of primary and secondary
lymphoid tissues. No other normal tissue was seen to stain
with either.
Reactivity of BU-12 with malignant B cells
Tumour cells from all 400 cases of B-cell chronic lymphocytic
leukaemia, 20 cases of pre-B-cell acute lymphoblastic
leukaemia and 159 cases of B-cell non-Hodgkin's lymphoma
were positive for CD19 expression detected with BU12
antibody.
Protein synthesis inhibition in target and non-target cells by
BU12-SAPORIN
BU12-SAPORIN inhibited protein synthesis in target
NALM-6 cells in a dose-dependent manner (Figure 3). The
IC50 value was achieved at a BU12-SAPORIN concentration
a
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of 0.0069 ytg ml-'. Native BU12 antibody used over the same
concentration range had virtually no effect on protein syn-
thesis levels in NALM-6 cells. Similarly, the irrelevant anti-
CD7 immunotoxin HB2-Sap used over the same concentra-
tion range as BU12-SAPORIN had no significant effect on
protein synthesis levels in NALM-6 cells. The IC50 value for
saporin alone was 2.4pgml-1 and therefore the calculated
increase in cytotoxicity of BU12-SAPORIN over native
saporin was 347-fold.
Figure 4 shows protein synthesis levels in the CD19-
CD7+ T-ALL cell line HSB-2 exposed to increasing concent-
rations (0.00 1-10 Ig ml-) of BU12-SAPORIN or HB2-Sap.
BU12-SAPORIN did not inhibit protein synthesis in HSB-2
cells at any of the concentrations investigated. As expected,
the anti-CD7 immunotoxin HB2-Sap, inhibited protein syn-
thesis in CD7+ HSB-2 cells in a dose-dependent manner with
an achieved IC50 value of 0.014jig ml-'.
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Figure 3 Inhibition of protein synthesis in CDl19 CD7-
NALM-6 target cells by BU12-SAPORIN (0 0), HB2-SAP
(0 O), BU12 antibody (A A) or saporin (V V).
Error bars represent one standard deviation from the mean result
obtained for triplicate cultures for each data point.
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Figure 2 Flow cytometry profiles of CD19+ NALM-6 cells stained with BU12 antibody at 10 fig ml
' (a) or I jig ml-l (b) or with
BU12-SAPORIN immunotoxin at 10 jig ml-' (c) or I fig ml-' (d). Unstained control NALM-6 cells are shown as a broken line.
Figures in paraentheses refer to the mean fluorescent intensity in arbitrary units.
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Figure 4 Inhibition of protein synthesis in CD19- CD7+ HSB-2
target cells by BU12-SAPORIN (0 *), HB2-SAP (0 0)
or saporin (V V). Error bars represent one standard devia-
tion from the mean result obtained for triplicate cultures for each
data point.
NALM-6 and HSB-2 leukaemia in SCID mice
SCID mice injected intravenously with NALM-6 cells
developed hind leg paralysis which progressed to quad-
raplegia, leading to eventual death. In previous studies we
demonstrated that all animals that developed hind leg
paralysis became moribund and died with NALM-6 cells
infiltrating the CNS and bone marrow 7-10 days following
onset of paralysis. Near-identical findings for the behaviour
of NALM-6 tumour cells in SCID mice have been reported
by Uckun et al. (1992). For humane purposes we painlessly
killed experimental animals in these studies when they first
showed signs of paralysis and the survival figures expressed
thus represent survival up to this point. Figure 5 shows the
direct relationship between the number of NALM-6 cells
injected and survival time, with animals receiving the greatest
number of cells surviving for the shortest period.
We have previously described in detail the characteristics
of acute T-cell HSB-2 leukaemia in SCID mice (Morland et
al., 1994). Animals with disseminated HSB-2 leukaemia have
multiorgan involvement but generally do not develop
neurological problems because HSB-2 tumour cells do not
infiltrate the CNS as extensively as NALM-6 cells. Animals
with HSB-2 leukaemia thus tend to develop a wasting-type
disease and become moribund as essential organs are
infiltrated.
Therapy ofSCID-NALM-6 mice with BU12-SAPORIN
Figure 6a shows the survival of groups of SCID mice injected
i.v. with 2 x 106 NALM-6 cells followed by sham therapy
with PBS, BU12-SAPORIN, the irrelevant anti-CD7 saporin
immunotoxin HB2-Sap or native BU12 antibody + saporin.
Sham-treated control animals had a median survival time of
40.2 days with all animals dead within this group by 45 days.
Treatment with BU12-SAPORIN led to a significant prolon-
gation in survival (sham-treated controls vs BU12-SAPORIN
therapy P = 0.000723 by log-rank analysis) of SCID-
NALM-6 mice with 40% of animals alive and apparently
disease free at the termination of the experiment at 110 days.
Treatment with unconjugated BU12 antibody + saporin also
had a significant therapeutic effect (sham-treated controls vs
BU12 + saporin treatment P = 0.00413), animals within this
treatment group having a median survival of 63.3 days but
with all animals dead by 95 days. Comparison of the BU12-
SAPORIN IT treatment group with the BU12 + saporin
group by log-rank analysis revealed a significant difference
between the two (P = 0.0525) with BU12-SAPORIN treat-
ment being obviously superior. The irrelevant anti-CD7
immunotoxin HB2-SAP had no therapeutic effect in SCID-
NALM-6 mice, animals within this group dying at approx-
Figure 5 Survival of groups of SCID mice injected intravenously
with various numbers of NALM-6 leukaemia cells. Number of
NALM-6 cells I07; l0;
104.
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Figure 6 Survival curves for groups of SCID mice following i.v.
challenge with 2 x 106 NALM-6 (a) or HSB-2 cells (b) followed 7
days later by treatment on 3 alternate days with BU12-
SAPORIN (- -), BU12 antibody + saporin (......), HB2-Sap
(- - --) or PBS (
imately the same rate as sham-treated controls with a median
survival time of 41.3 days.
Therapy studies with BU12-SAPORIN were also under-
taken in SCID mice bearing the CD19- CD7+ T-ALL cell
line HSB-2 and the results are shown in Figure 6b. BU12-
SAPORIN had no therapeutic effect in this SCID-HSB-2
model, with treated animals dying at approximately the same
rate as sham-treated controls (median survival times of 57.6
days and 58 days respectively). In contrast, as reported by us
previously, treatment with the anti-CD7 immunotoxin HB2-
Sap led to a significantly prolonged survival with 90% of
animals within this therapy group alive at 150 days (Flavell
et al., 1994).
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Discussion
These preclinical studies with BU12-SAPORIN have clearly
demonstrated the selective cytotoxicity of this immunotoxin
for CD19+ but not CD19- human leukaemia cell lines. In
vitro assays revealed that BU12-SAPORIN inhibited protein
synthesis in CD19+ NALM-6 target cells in a dose-dependent
manner but had no effect on protein synthesis levels in the
CD19- T-ALL cell line HSB-2.
In therapy studies in SCID mice with disseminated CDl9+
NALM-6 leukaemia, BU12-SAPORIN had a significant
therapeutic effect in comparison to PBS sham-treated
animals. In contrast treatment of NALM-6-bearing SCID
mice with the irrelevant anti-CD7 immunotoxin HB2-Sap
had no beneficial therapeutic effect. BU12 antibody given
together with saporin in a molar ratio equivalent to that
found in the immunotoxin did have a positive therapeutic
benefit with a prolongation in mean survival of these animals
by an additional 50 days over sham-treated controls. How-
ever, all animals in the antibody + saporin therapy group did
eventually succumb with leukaemia in contrast to the 40%
survivors in the BU12-SAPORIN therapy group. Log-rank
analysis revealed that the therapeutic outcome of BU12-
SAPORIN and BU12 antibody + saporin treatment was
significant compared with the sham-treated control group but
also, as might be predicted, that BU12-SAPORIN therapy
was significantly superior to BU12 + saporin therapy (P=
0.0525).
Similar preclinical findings have been reported for the
anti-CD19-PAP immunotoxin B43-PAP(Uckun et al., 1992).
Other workers have also demonstrated a therapeutic effect of
naked murine antibody in SCID mouse models of human
haematological malignancy, particularly immunotoxins
targeting against CD7 (Fishwild et al., 1992; Morland et al.,
1994) on T-cell tumours and CD19 on B-cell tumours
(Ghetie et al., 1994). However Uckun et al. (1992) reported
that the anti-CD19 antibody B43 had no therapeutic effect
against NALM-6 cells in SCID mice. The fact that BU12
antibody has a minimum cytotoxic effect on NALM-6 cells in
vitro, and yet has a major therapeutic effect in vivo, points to
the likely involvement of host effector mechanisms which
might include complement-mediated killing and/or antibody-
dependent cellular cytotoxicity through recruitment of
natural killer (NK) cells which are present in SCID mice
(Dorshkind et al., 1985). Contrary to this Ghetie et al. (1994)
have demonstrated in vitro that a variety of anti-CD19
antibodies, including BU-12, inhibit protein synthesis and
cellular proliferation in the CDl9+ B-cell line Daudi and
have concluded that this is the major in vivo anti-tumour
mechanism. However, it is clear from our in vitro studies that
this effect does not occur with NALM-6 cells. Further
confirmation of the absolute specificity of BU12-SAPORIN
only for CD19+ cells was provided by the total lack of
therapeutic effect of BU12-SAPORIN in SCID mice bearing
the CD19- CD7+ T-ALL cell line HSB-2.
Functionally CD19 antigen is a membrane receptor
involved in the regulation of B-cell proliferation (DeRie et
al., 1989). It is an ideal target molecule for B-cell tumours,
being expressed on all human B-cell subpopulations (with the
exception of plasma cells) and B-cell precursors before CD10
expression, making it the earliest B-cell differentiation struc-
ture appearing in ontogeny (Uckun et al., 1988). As our
series of B-cell lymphomas demonstrates, CD19 expression
detected by BU-12 antibody occurs in the majority of tumour
cells within a variety of B-cell non-Hodgkin's lymphoma
cases and these data have been confirmed independently by a
number of laboratories. CD19 detected by BU-12 was
strongly expressed by all 20 cases of cALL studied, and
pooled data from the Third Leucocyte Typing Workshop
indicates that almost 60% of cALL cases stain positively
with BU-12. As our extensive normal tissue staining studies
have shown, BU-12 does not stain any other normal tissue
outside the B-cell compartment and therefore inappropriate
targeting, as has occurred with other immunotoxins which
have recognised cross reacting epitopes on essential normal
tissue structures (Weiner, et al., 1989), should not occur with
BU12-SAPORIN and indeed the clinical experience with
other anti-CD19 immunotoxins attests to this. It has, how-
ever, been shown that the anti-CD19-blocked ricin
immunotoxin B4-bR administered to B-cell lymphoma
patients results in dramatic reductions in normal circulating
B-cells which are obviously eliminated by the immunotoxin
(Grossbard et al., 1992). However, normal levels of cir-
culating CD19+ B-cells were restored within 25 days follow-
ing cessation of treatment. We expect that patients treated
systemically with BU12-SAPORIN are also likely to show
falls in normal circulating B-cells but as CD19 is not exp-
ressed on the B-cell stem cell population regeneration to
within normal levels should occur rapidly. The existence of
such a large pool ofCD19+ normal B-cells in patients treated
with BU12-SAPORIN will unfortunately provide a barrier to
therapeutic effectiveness, with normal B-cells competing with
malignant target cells for binding and resulting in consump-
tion of immunotoxin. One major shortcoming of the SCID
model of human pre-B-cell acute lymphoblastic leukaemia
described here is the lack of a normal B-cell population that
expresses human CD19. This model cannot therefore predict
the effects such a normal B-cell population would have on
BU12-SAPORIN pharmacokinetics and clearance in man.
Recent phase I trials with anti-CD19 immunotoxins in
patients with B-cell malignancies have demonstrated activity
of these therapeutics in a significant proportion of patients
treated. In particular the B43-PAP immunotoxin, comprising
the anti-CD19 antibody B43 coupled to the single-chain
ribosome-inactivating protein pokeweed antiviral protein, has
shown promising activity in cALL patients (Uckun, 1993).
The preclinical findings we have described here for BU12-
SAPORIN are encouraging and provide a sound rationale
for investigating the activity of BU12-SAPORIN in a formal
clinical trial of patients with CD19+ B-cell tumours.
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